Pomegra
Intuitive Surgical shares fell 7% to 13% after hours on Oct. 20 as a $450 million antitrust settlement and planned da Vinci price cuts overshadowed a Q3 beat.
- Q3 revenue rose 22% to $3.05 billion and non-GAAP EPS reached $3.00, both above consensus.
- A $450 million antitrust settlement cut GAAP EPS by $0.99 to $1.49.
- Planned pricing changes would lower da Vinci instrument revenue per procedure by about 3% to 5%.
Lead
Intuitive Surgical (NASDAQ: ISRG) reported third-quarter results on Oct. 20 that beat Wall Street forecasts, yet the stock dropped between 7% and 13% in extended trading. The maker of the da Vinci surgical robot posted revenue of $3.05 billion, up 22% from $2.51 billion a year earlier and ahead of the roughly $2.91 billion consensus. Non-GAAP earnings of $3.00 per share compared with expectations near $2.65. Investors focused instead on a one-time settlement charge and a decision to reduce the price of the instruments and accessories that drive the company's recurring revenue.What Happened in Intuitive Surgical's Third Quarter?
Intuitive Surgical grew procedures, system placements and margins in the quarter. Worldwide procedures rose about 15%, with da Vinci procedures up about 14% and Ion lung-biopsy procedures up about 31%. U.S. da Vinci growth was about 10%, while growth outside the U.S. was about 20%.
The company placed 546 da Vinci systems, up from 427 a year earlier. Of those, 315 were the newer da Vinci 5. The da Vinci installed base reached 12,094 systems, up 12%. Instruments and accessories revenue rose 18% to $1.80 billion.
Non-GAAP gross margin widened to 69.9% from 68.0%. Non-GAAP operating income was $1.27 billion, compared with $975.9 million in the year-earlier quarter. Cash and investments ended the period at $6.80 billion, down $1.83 billion from the start of the quarter.
How Large Is the Antitrust Settlement?
The settlement is a $450 million one-time payment, which reduced GAAP earnings by $347 million after tax, or $0.99 per diluted share. It resolves the "In re: da Vinci Surgical Robot Antitrust Litigation" class action. The company admitted no liability or wrongdoing. The agreement also includes mutually agreed injunctive relief and remains subject to court approval.
The charge explains the gap between adjusted and reported results. GAAP net income fell to $522.8 million, or $1.49 per share, from $704.4 million, or $1.95, a year earlier. GAAP operating income fell to $592.6 million from $759.7 million.
Why Did Investors Sell the Stock Despite the Beat?
Investors sold because the pricing action and unchanged volume outlook raised questions about future profit growth. The company said it would reduce da Vinci instrument and accessory revenue per procedure by roughly 3% to 5% on a mix-constant basis once the changes are fully implemented. Those consumables are the core of the business's recurring revenue model, so lower prices cut into the highest-margin part of each procedure.
The volume outlook also did not improve. The company kept its 2026 da Vinci procedure growth forecast at 14% to 15% and said results should land near the midpoint. After a quarter of roughly 14% growth, that signaled no acceleration. The stock had entered the report with a trailing price-to-earnings multiple near 50, below its five-year median of about 70, which left less room for a muted outlook.
What Does the Guidance Imply for Margins?
The guidance implies steady but not expanding profitability. For 2026, the company expects non-GAAP gross margin of 68.7% to 69.3%, including a tariff impact of about 0.9 percentage points. It expects non-GAAP operating expense growth of 11% to 13%.
Operating expenses are projected to grow more slowly than the 22% revenue increase posted in Q3. That supports operating leverage this year. Over time, a 3% to 5% reduction in instrument revenue per procedure would pressure gross margin unless procedure growth, manufacturing efficiency or system placements offset it.
Strategic Context
The price cuts come as the company expands its installed base and pushes the da Vinci 5 platform. Lower per-procedure costs could make robotic surgery easier for hospitals to adopt and for existing customers to use more heavily, particularly outside the U.S., where growth is already running at about 20%. They would also lessen the commercial pressure that underpinned the antitrust claims over instrument pricing and servicing.
Of the 546 placements, 291 were operating leases, and 160 of those were usage-based. That shifts part of the revenue mix toward recurring, procedure-linked payments and makes procedure volume more important to results.
Outlook
Intuitive Surgical enters the fourth quarter with strong demand, a 12% larger da Vinci installed base and a legal overhang largely resolved, pending court approval. The central question for investors is whether higher procedure volumes can absorb a 3% to 5% cut in instrument revenue per procedure. Margin guidance for 2026 holds, but the pricing change shifts focus to 2027 and beyond. The stock's reaction shows the market is pricing that trade-off ahead of any evidence on volume.
Mentioned tickers: ISRG
